Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 78

Warning: Trying to access array offset on value of type bool in /www/wwwroot/www.medtourcn.com/wp-content/themes/medical-directory/framework/theme/medicaldirectory-image.php on line 79

4 months ago CAR-T

Breakthrough Therapy Brings New Hope: Swiss Patient Thomas Begins CAR-T Treatment at Tongji Hospital, Wuhan

Professor Li Chunrui’s team at Tongji Hospital in Wuhan successfully conducted a case of chimeric antigen receptor T-cell (CAR-T) immunotherapy for a patient with relapsed and refractory multiple myeloma, offering new life to Swiss patient Thomas.

Thomas, a 54-year-old patient from Switzerland, has been battling multiple myeloma for nearly ten years. Initially diagnosed in 2016, he has endured severe bone pain and undergone multiple rounds of systemic chemotherapy and monoclonal antibody therapy. Although his condition was temporarily controlled, repeated relapses, with the most recent in 2022, made treatment increasingly challenging.

However, the global development of CAR-T therapy has reignited hope. The introduction of FUCASO (Eque-cel), the first fully human CAR-T product in mainland China, has brought new light to Thomas. This groundbreaking treatment not only boasts low immunogenicity but also offers prolonged efficacy, enabling patients to return to a high quality of life.

Thomas ultimately chose to receive the cutting-edge CAR-T therapy at Tongji Hospital, seeking a fundamental breakthrough in his treatment. The apheresis procedure was conducted by the hospital’s top hematology team, who possess international-level expertise and place special emphasis on patient-specific needs and treatment safety. The attending physician elaborated on the apheresis process in an interview, saying, “We precisely collected T-cells from Thomas’s body, then modified these cells in a controlled environment to specifically target multiple myeloma cancer cells. The use of FUCASO greatly enhanced the treatment’s specificity and success rate.”

Thomas expressed high recognition and appreciation for the hospital team’s professionalism and the transparency of the treatment process. Tongji Hospital leveraged its advanced technology and equipment to provide Thomas with a smooth and efficient apheresis experience, ensuring high-quality T-cell collection and paving the way for the subsequent treatment.

Thomas is now filled with confidence and anticipation, looking forward to the new life that CAR-T therapy promises. This new beginning marks a significant step in his treatment journey, injecting new hope into his path to recovery.

We will continue to follow up on the patient’s subsequent treatment and report on the progress.

CART MultipleMyeloma FUCASOJourney Equecel TongjiHospital CancerSurvivor BloodCancer Immunotherapy FullyHumanCART CancerTreatment

4 months ago Myeloma , patient story

The Journey of an Indian Cancer Patient Seeking Treatment in China: Gratitude to Be Brought Back to India

patient story

“Before coming to China for treatment, I was filled with worries. My condition was not optimistic, and I was afraid I might never see my family again… But after arriving here, everyone I met was so warm and welcoming. The doctors are not only professional but also incredibly patient. I am now truly, truly happy, and I will bring this gratitude back to India.” — Ms. Savita

This is the true story of Ms. Savita from India, a multiple myeloma patient. Her journey to seek medical treatment was long and arduous, and she was often moved to tears when recounting it.

In 2012, Savita was diagnosed with multiple myeloma in India. After undergoing various treatment methods, her condition relapsed, and doctors estimated she had only six months to live. Desperate and with nowhere else to turn, she decided to seek hope in China.

At the Jiangsu Provincial People’s Hospital North Branch, Savita successfully joined a clinical trial and underwent T-cell therapy. One month after treatment, evaluation results showed that her lesions had almost completely disappeared, indicating significant improvement.

When she was first admitted, Savita was bedridden, suffering from severe bone pain, and required daily injections of strong painkillers. Now, she can live like a healthy person and even went on a trip to Shanghai with her husband, Inder.

Even more joyful is the fact that her daughter will be getting married next January. Reborn with a new lease on life, she is filled with hope for the future, and her joy is palpable.

Savita’s husband, Inder, shared their medical journey in China with a group of multiple myeloma patients in India, and many are hopeful to come to China for treatment.

Ms. Savita’s story is a journey filled with hope and gratitude. She will bring this gratitude back to India, inspiring more people to see the light of hope.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: 137 1795 9070

Email: doctor.huang@globecancer.com

#IndianPatient #ChinaTreatment #CancerRecovery #NewLife #Gratitude #MedicalMiracle #LightOfHope

4 months ago patient story , Myeloma

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient

Patient story

Subtitle: Fighting for Love! A story of miraculous rebirth after all treatment options failed for a late-stage multiple myeloma patient in Thailand, who underwent CAR-T therapy in China.

Preface: When all treatment options had been exhausted, cancer progressed rapidly, and doctors regretfully said that Ms. M had no response to any medication. This situation could only lead to palliative care, meaning Ms. M had no chance to fight this disease anymore; her life was now on borrowed time. Fortunately, Ms. M’s family found new hope in China – CAR-T therapy. With the companionship of her family, Ms. M came to China and underwent the world’s first fully human BCMA CAR-T therapy. In just 22 days after treatment, all tumors miraculously disappeared, achieving complete remission (CR), and Ms. M was given a new lease on life!

In June 2021, the life of 58-year-old Ms. M experienced persistent back pain for over months. After detailed examinations at the hospital,resulting in a diagnosis of multiple myeloma. To quickly control the condition, Ms. M received treatments including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation.

In June 2023, the disease relapsed and Ms. M did not respond to any of these treatments. Local doctors informed Ms. M’s family that apart from palliative care, they were powerless, indicating that Ms. M’s life was now on borrowed time! Just as Ms. M was in dire straits, on June 30, 2023, the world’s first fully human BCMA CAR-T therapy – Equecabtagene Autoleucel, was shockingly launched in China, becoming a lifesaving straw for her. Ms. M and her family decided to seek treatment in China.

In September 2023, Professor Li Ping’s team at Shanghai Tongji Hospital developed a personalized Equecabtagene Autoleucel(BCMA CAR-T) therapy plan for Ms. M.

On September 8, 2023, Ms. M finally officially entered the CAR-T treatment process. After all examination items met the requirements, single-cell collection was performed first.

Bridge therapy began on September 11, 2023;

Local radiotherapy to relieve bone pain started on September 24, 2023;

Fludarabine plus cyclophosphamide chemotherapy was administered from October 9-12, 2023;

Finally, on October 14, a small bag of milky-white liquid was infused into Ms. M’s body. The doctor said that inside were billions of “special” T cells that could precisely kill multiple myeloma cells. Once inside the body, they would initiate a mode of frenzied sweeping, wiping out cancer cells completely.

What shocked everyone was that the examination results 22 days after CAR-T treatment showed that Ms. M had achieved hematologic CR, meaning that no cancer cells were detected in her blood. Her pain and anemia were also reversed. It was simply a miracle!

Every day now is precious to Ms. M. She can go shopping, chat with her family, enjoy delicious food with her family, and travel around the world with them, returning to the happy times before she fell ill. The only difference is that Ms. M and her family visit a fixed destination every month now – Shanghai, China. They have become accustomed to hearing the sacred announcement from the doctors here: no cancer in her body, continuing remission.

This is a microcosm of countless cancer patients overcoming the disease. The emergence of CAR-T cell therapy has brought new hope to cancer patients. I believe that in the future, more patients will be able to regain a new life like Ms. M.

Reference：

[1]Yuting Yan, et al. Blood Adv. 2019 Oct 8;3(19)：2895-2904.

[2] 2023 IMS. P-290.

4 months ago patient story

22 Days from Desperation to Rebirth! Chinese CAR-T Therapy Creates Survival Miracle for Thai Multiple Myeloma Patient

Patient story

In July 2017, 58-year-old Ms. M was diagnosed with multiple myeloma. After receiving treatments at the best hospital in Thailand, including PCD, DVD, bortezomib and lenalidomide, autologous hematopoietic stem cell transplantation. The disease rapidly relapsed. Local doctors informed Ms. M’s family that apart from palliative care, they were powerless.

Just as Ms. M was in dire straits, on June 30, 2023, the world’s first fully human BCMA CAR-T therapy – Equecabtagene Autoleucel, was shockingly launched in China, becoming a lifesaving straw for her. Ms. M and her family decided to seek treatment in China.

In September 2023, Professor Li Ping’s team at Shanghai Tongji Hospital developed a personalized Equecabtagene Autoleucel(BCMA CAR-T) therapy plan for Ms. M. What shocked everyone was that the examination results 22 days after CAR-T treatment showed that Ms. M had achieved hematologic CR, meaning that no cancer cells were detected in her blood. Her pain and anemia were also reversed. It was simply a miracle!

Reference：

[1]Yuting Yan, et al. Blood Adv. 2019 Oct 8;3(19)：2895-2904.

[2] 2023 IMS. P-290.

4 months ago Myeloma , patient story

Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai

Key Steps in Precision Treatment: A Detailed Overview of CAR-T Infusion for a Russian Patient at Jiahui in Shanghai**

Vladimir Borzenkov, a 68-year-old patient from St. Petersburg, Russia, recently completed the core phase of CAR-T therapy—reinfusion—at Jiahui International Hospital in Shanghai. This crucial step involves reinfusing T-cells, which have been genetically modified to recognize and attack specific cancer cells, back into the patient’s body. For Mr. Vladimir, who has been battling his condition for over five years, this step is particularly significant.

Before the reinfusion, the medical team conducted a comprehensive physical assessment to ensure his body could withstand the procedure. Despite being in his sixties, Vladimir’s determination and desire for a cure helped him overcome any obstacles posed by his age. His journey began in December 2017 with back pain, which progressively worsened over several months. By February 2018, multiple bones, including his spine, sternum, and clavicle, showed signs of deterioration. Although this period seemed like a relentless trial, Vladimir never lost his faith in life. Now, at this critical juncture, he is filled with hope for the future.

For this treatment, Jiahui Hospital utilized FUCASO (Eque-cel), a fully human CAR-T therapy known for its unique low immunogenicity and lasting efficacy, providing therapeutic advantages for the patient. During the reinfusion process, Jiahui Hospital demonstrated advanced capabilities in monitoring and managing adverse reactions. The hospital is equipped with the latest monitoring technology and a highly experienced medical team, ensuring that any potential adverse reactions are promptly identified and managed, thus ensuring the safety and effectiveness of the treatment. This high level of monitoring and detailed attention to the patient’s health made Vladimir’s treatment process not only efficient but also safe.

Through his experience at Jiahui International Hospital, Vladimir witnessed the powerful potential of CAR-T therapy and the significant advantages of FUCASO. He is now filled with hope for the future treatment outcomes. This treatment marks not only a significant milestone in his personal battle against cancer but also showcases Jiahui’s expertise in CAR-T technology and excellent patient care.

#CART #MultipleMyeloma #FUCASOJourney #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART #CancerTreatment

5 months ago patient story

Ключевой этап точечного лечения: Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи

Ключевой этап точечного лечения:

Подробное объяснение афереза CAR-T для российского пациента в Шанхайской Международной больнице Жияхуи

Владимир Борзенков, 68-летний пациент из Санкт-Петербурга, в последнее время прошел важный этап лечения CAR-T в Международной больнице Жияхуи в Шанхае – аферез. Этот процесс включает в себя сбор Т-клеток из организма пациента для дальнейшей генетической модификации и увеличения. Владимир выразил благодарность профессионализму лечебной команды и прозрачности лечебного процесса, что не только сняло его беспокойство, но и увеличило уверенность в успехе лечения. Больница Жияхуи использовала свои передовые устройства и технологии, чтобы обеспечить Владимиру плавный и эффективный опыт афереза, гарантируя высококачественный сбор Т-клеток и заложив прочный фундамент для следующих этапов лечения.

#CART #МножественнаяМиелома #ОдобрениеФУКАСО #Эквесел #БольницаЖияхуи #Шанхай #ВыжившийОтРака #КровяноеРак #Иммунотерапия #ПолностьюЧеловеческийCART

#CART #MultipleMyeloma #FUCASOapproval #Equecel #JiahuiHospital #Shanghai #CancerSurvivor #bloodcancer #Immunotherapy #FullyHumanCART

5 months ago CAR-T , patient story

International Standards for Innovative Medical Services: The Initial Experience of Singaporean Patients at Jiahui International Hospital

Title: International Standards for Innovative Medical Services: The Initial Experience of Singaporean Patients at Jiahui International Hospital

Content:

Singaporean patient, Ms. Teresa, recently experienced unique CAR-T therapy at Jiahui International Hospital in Shanghai. From scheduling to consultation, Jiahui Hospital demonstrated its top-notch service and medical expertise. During her initial visit, Teresa was impressed by the hospital’s modern facilities and the professionalism of the medical team.

The comprehensive assistance provided by the hospital, from language translation to medical consultation, ensured her comfort and peace of mind throughout the entire treatment process. Teresa shared, “From the moment I stepped into Jiahui, every meticulous care made me feel warm.” This visit not only strengthened her trust in Chinese medical services but also laid a solid foundation for her subsequent CAR-T therapy journey.

We will continue to monitor the progress of the patients’ treatment and provide follow-up reports.

#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

5 months ago patient story

创新医疗服务的国际标准：新加坡患者在嘉会医院的初体验

新加坡患者Teresa女士近期在上海嘉会国际医院体验了独特的CAR-T治疗。从预约到接诊，嘉会医院展示了其一流的服务和医疗水平。首次就诊中，Teresa对医院的现代化设施和医护团队的专业性印象深刻。医院提供的全面协助，从语言翻译到医疗咨询，确保了她在整个就诊过程中的舒适与安心。Teresa分享道：“从第一次步入嘉会，每一次细致的关怀都让我深感温馨。”此行不仅强化了她对中国医疗服务的信任，也为她后续的car-t治疗之路打下了坚实的基础。

我们将持续关注患者的治疗后续，并跟进报道。

#CART #CARTTherapy #HopeReborn #FUCASOApproval #Equecel #MultipleMyeloma #JiahuiHospital #Shanghai #Immunotherapy #MedicalInnovation #MedicalBreakthrough #CancerTreatment #FullyHumanCART

6 months ago patient story

Hope Rekindled: The Remarkable Journey of a Pakistani Multiple Myeloma Patient in China

Hope of patient

“When I first arrived, I couldn’t walk and had a lot of pain in my chest and back. Now, I don’t have these symptoms anymore, and I can walk for more than ten minutes every day.”

Meet Julian, a patient from Pakistan who faced the daunting challenge of a relapse in his battle against Multiple Myeloma. Despite undergoing various treatments, relief seemed elusive.

Julian’s wife stumbled upon groundbreaking research published by Xuzhou Medical University, highlighting innovative cell therapy for Multiple Myeloma developed by the Tumor Biotherapy Research Institute and affiliated hospitals.

Seeking further treatment, Julian and his wife embarked on a journey to Xuzhou Medical University Affiliated Hospital. Upon arrival, thorough examinations were conducted to assess his condition and formulate a tailored treatment plan.

Julian underwent T-cell collection at the Hematology Department’s Cell Collection Room, with the harvested cells processed into CAR-T cells by Xuzhou Medical University’s Cancer Research Institute. Two weeks later, he received an infusion of immune cells (CD19CAR-T cells, BCMACAR-T cells).

A month later, bone marrow cytology revealed complete remission of the primary disease. His attending physician continued medical observations, confirming positive treatment outcomes through comprehensive examinations.

“Previously, I couldn’t sit like this, and walking was very difficult. It was also very uncomfortable to lie down.”

”After receiving CAR-T treatment, you can see that I can now sit normally, walk normally, and my mobility is gradually increasing.

My improvement is very significant.”

From treatment initiation to Julian’s discharge and return home, the entire process took just one and a half months.

Julian’s journey stands as a beacon of hope, showcasing the transformative potential of innovative medical interventions in the fight against Multiple Myeloma.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

WhatsApp: +8613717959070

Email: doctor.huang@globecancer.com

#MiracleTreatment #CancerResearch #MedicalInnovation #Hopeofpatient #patientstory #XuzhouMedicalUniversity #MultipleMyelomaAwareness #MultipleMyeloma #Chinesemedical

6 months ago Myeloma

The world’s first #CART therapy approved for second-line treatment of multiple myeloma is claimed by a Chinese pharmaceutical company

Mutiple myeloma

#Legend Biotech

How to advance #CARTcell therapy to frontline treatment is the goal every CAR-T company strives for. On April 5, 2024, local time, Chinese pharmaceutical company Legend Biotech (LEGN.NS) shared exciting news as the U.S. Food and Drug Administration (#FDA) officially approved #ciltacabtageneautoleucel for treating relapsed or refractory multiple myeloma patients. This significant decision brings new hope to patients who have undergone first-line treatment and developed resistance to standard therapies.

#Ciltacabtagene autoleucel

Ciltacabtagene autoleucel becomes the world’s first CAR-T product approved for second-line treatment! This milestone event paves the way for Legend Biotech to enter the global CAR-T market. What’s even more inspiring is that just the day before, the FDA approved BMS’s CAR-T therapy Abecma for third-line treatment of multiple myeloma. The approval of ciltacabtagene autoleucel signifies the strong competitiveness and innovation capabilities of Chinese pharmaceutical companies in the CAR-T field.

Marketing

As early as February 28, 2022, ciltacabtagene autoleucel was first approved for marketing in the United States for the treatment of relapsed or refractory multiple myeloma in adults. As a pioneer of Chinese original CAR-T cell therapy, the successful market launch of this drug has won new glory for China’s biopharmaceutical industry. Currently, ciltacabtagene autoleucel is marketed in the United States, European Union, and Japan, and is also undergoing regulatory review in China, expected to be marketed domestically soon.

Personalized Immunotherapy

The CEO of Legend Biotech stated that the expanded indication of ciltacabtagene autoleucel is expected to change the treatment landscape of multiple myeloma, providing physicians and patients with a personalized immunotherapy option for early treatment. Multiple myeloma is an incurable and progressive hematologic malignancy, thus urgently requiring innovative treatment options, for which ciltacabtagene autoleucel is designed.

HOPE

The successful approval of ciltacabtagene autoleucel not only brings hope to patients but also outlines a new chapter for the future development of CAR-T therapy. In this hopeful moment, let’s look forward to CAR-T technology bringing health and happiness to more patients in the future!

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com,

WhatsApp: 137 1795 9070

#LegendBiotech #CARTcell #MultipleMyelomaTreatment #Innovation #Hope

6 months ago Myeloma

#EBMT Conference Reveals the Best CAR-T Therapy for Multiple Myeloma – Equecabtagene Autoleucel

Multiple myeloma

Introduction:

In recent years, there has been a breakthrough in the research of #CART therapy for relapsed and refractory #multiplemyeloma (RRMM). This treatment method holds promise to address the challenges of inadequate response depth and short duration of response in #RRMM patients, offering hope for achieving minimal residual disease (#MRD) negativity and functional cure in this population.

Key Findings at EBMT:

The upcoming 50th European Society for Blood and Marrow Transplantation (EBMT) congress is set to unveil abstracts shedding light on the efficacy of targeted #BCMA CAR-T therapies. A recent abstract titled “Indirect Comparison of the Effectiveness of Targeted BCMA CAR-T Products in RRMM (#MAIC)” for the first time reveals efficacy comparisons among four BCMA CAR-T products. The study demonstrates that Equecabtagene Autoleucel outperforms other BCMA CAR-T therapies in terms of overall response rate (#ORR) and complete response (#CR) rate, offering significant hope for RRMM patients.

#Equecabtagene Autoleucel: Pioneering Fully-human BCMA #CARTTherapy:

#EquecabtageneAutoleucel, the world’s first approved Fully-human BCMA CAR-T therapy, received priority review and approval in China on June 30, 2023. The MAIC analysis underscores its favorable efficacy. This article provides a systematic analysis of the efficacy data of Equecabtagene Autoleucel in the Chinese population over the past two years, as revealed in the dynamic disclosures at various international academic conferences post-approval.

Efficacy Data Highlights:

– In the #FUMANBA-1 Ib/II clinical study conducted in China, the sCR/CR rate reached an impressive 82.4% among RRMM patients.

– The latest data presented at the 2023 International Myeloma Society (#IMS) conference demonstrated a MRD negativity rate of 97.8% among the enrolled patients, indicating substantial tumor burden reduction.

– With a median follow-up of 18.07 months, long-term efficacy data showcased remarkable outcomes, including a median PFS not yet reached, 12-month continuous MRD negativity rate of 81.7%, and 12-month PFS rate of 85.5%.

Differentiating Factors:

– Equecabtagene Autoleucel exhibited shorter median time to response (#TTR) compared to other CAR-T therapies, indicating faster onset of action.

– The dissociation kinetics of Equecabtagene Autoleucel closely resemble those of natural T cells, facilitating efficient activation, killing, and proliferation within the body.

– Its rapid dissociation pattern minimizes CAR-T cell exhaustion, ensuring sustained efficacy and long-term surveillance against tumor recurrence.

Conclusion:

The emergence of Equecabtagene Autoleucel heralds a new era in CAR-T therapy for RRMM, offering superior efficacy and durable responses. With its unique structural advantages and promising clinical data, Equecabtagene Autoleucel stands as a beacon of hope for RRMM patients worldwide, bringing them closer to achieving disease control and improved quality of life.

To assess whether the condition is suitable for CAR-T or clinic therapy, you can submit Advanced Medicine in China for preliminary evaluation!

Email: doctor.huang@globecancer.com

WhatsApp: +8613717959070

#chineseMedicine #chineseresearch #cancerresearch #cancertreatment #myeloma #bloodtumor #cancer #cancerreseach

6 months ago patient story , Myeloma

🌈Treatment Across Continents: American Myeloma Patient Finds New Life in China!🌈

cancer fight

🌟Mr. C from California, USA

It’s yet another heartening piece of news as Mr. C from California, USA, undergoes cross-border treatment at Jiangsu Province People’s Hospital in China, successfully overcoming multiple myeloma and embracing a new lease on life! After meticulous treatment spanning one and a half months, Mr. C, accompanied by his loved ones, has made a successful recovery and been discharged from the hospital, becoming the first American patient to be successfully treated with CAR-T cell therapy for multiple myeloma in China.

🌞New treatment method

Mr. C, a 56-year-old American who is passionate about sports, discovered he had multiple myeloma after sustaining sports-related injuries. Despite enduring several unsuccessful treatment attempts, he refused to give up and began seeking treatment opportunities worldwide. However, the exorbitant cost of treating multiple myeloma in the USA deterred him. After comparing prices and data of CAR-T therapy for multiple myeloma between the USA and China, he ultimately decided to explore the new treatment method at Jiangsu Province People’s Hospital.

🌤Upon arriving in China,

Mr. C not only received meticulous care from medical staff but also had the opportunity to explore the scenic beauty of cities such as Nanjing, Suzhou, and Hangzhou, experiencing the unique cultural charm of China. During the CAR-T cell therapy treatment process, Mr. C underwent a life-threatening cytokine storm, but with the emergency intervention of the medical team, he successfully weathered the storm. Today, he has recovered and been discharged from the hospital, though slightly fatigued, he is still filled with hope and gratitude.

🔥Hope and Courage

Although Mr. C’s treatment has concluded, follow-up work will continue, with the medical team maintaining contact with his family doctor to closely monitor treatment effectiveness and subsequent conditions. As medical personnel, they sincerely hope that this treatment will provide Mr. C with more opportunities for survival.

☀️Mr. C also expressed his desire to revisit China, specifically Nanjing, to visit the experts and nurses who treated him, and of course, to continue savoring Chinese cuisine. This journey of treatment across continents not only granted Mr. C a new lease on life but also showcased the unity and dedication of medical personnel from both China and the USA. May this touching story inspire more people and bring forth more hope and courage!

⭐️CAR-T therapy

To assess whether the condition is suitable for CAR-T therapy, you can submit pathology reports, treatment history, and discharge summaries to the Medical Department of <Advanced Medicine in China> for preliminary evaluation!

You can send electronic copies or photos of genetic testing reports and diagnostic reports to:

💌: doctor.huang@globecancer.com
📞WhatsApp 137 1795 9070

✨The Medical Department will contact you as soon as receive the reports.

#CARTtherapy #LymphomaTreatment #CompleteRemission #MedicalAdvancements #CancerResearch #CARTProgress #HopeForPatients #SurvivingLymphoma #HealthcareInnovation #PatientStories #CancerCure #CARTSuccess #MedicalBreakthrough #ImprovingOutcomes #LymphomaAwareness #FightAgainstCancer #CARTJourney #MedicalMilestone #LongTermSurvival #BeatingCancer #lymphoma #cancerawareness

Menu

Tags Archives: multiple myeloma